A5012936802- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Genomics and Diagnostics
- Gallbladder and Bile Duct Disorders
- Peptidase Inhibition and Analysis
- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Pancreatitis Pathology and Treatment
- Gastric Cancer Management and Outcomes
- Neuroendocrine Tumor Research Advances
- Cancer Immunotherapy and Biomarkers
- Fibroblast Growth Factor Research
- Viral-associated cancers and disorders
- Renal cell carcinoma treatment
- Radiomics and Machine Learning in Medical Imaging
- Cancer Mechanisms and Therapy
- Monoclonal and Polyclonal Antibodies Research
- Gastrointestinal Tumor Research and Treatment
- Epigenetics and DNA Methylation
- HER2/EGFR in Cancer Research
- Cancer, Hypoxia, and Metabolism
- Pancreatic function and diabetes
- Cancer Research and Treatments
- Cancer-related molecular mechanisms research
- Oral and gingival health research
University of Arizona Cancer Center
2019-2025
University of Arizona
2019-2025
University of Colorado Denver
2023
The University of Texas MD Anderson Cancer Center
2012-2022
Banner - University Medical Center Tucson
2020-2022
American Society of Clinical Oncology
2019
University of Michigan
2019
AbbVie (United States)
2019
Novartis (Switzerland)
2019
Merck Serono (Switzerland)
2019
Purpose No standard treatment exists for patients with cholangiocarcinoma whom first-line gemcitabine-based therapy fails. Fibroblast growth factor receptor 2 ( FGFR2) fusions/translocations are present in 13% to 17% of intrahepatic cholangiocarcinomas. BGJ398, an orally bioavailable, selective pan-FGFR kinase inhibitor, has shown preliminary clinical activity against tumors FGFR alterations. Methods A multicenter, open-label, phase II study ClinicalTrials.gov identifier: NCT02150967)...
To develop an evidence-based clinical practice guideline to assist in decision making for patients with advanced hepatocellular carcinoma (HCC).
Cholangiocarcinoma (CCA) is clinically heterogeneous; intra and extrahepatic CCA have diverse clinical presentations. Next generation sequencing (NGS) technology may identify the genetic differences between these entities molecular subgroups for targeted therapeutics.We describe successful NGS-based testing of 75 patients along with prognostic therapeutic implications findings. Mutation profiling was performed using either a) NGS panel hotspot regions in 46 cancer-related genes a 318-chip on...
<h3>Importance</h3> Administration of gemcitabine-cisplatin, the current standard therapy for advanced biliary tract cancers, results in median progression-free survival and overall 8.0 11.7 months, respectively. New treatments offering improved outcomes are therefore needed. <h3>Objective</h3> To evaluate association between addition nanoparticle albumin-bound (nab)–paclitaxel to gemcitabine-cisplatin treatment patients with cancer. <h3>Design, Setting, Participants</h3> This open-label,...
Biliary tract cancers (BTCs) typically present at an advanced stage, and systemic chemotherapy is often of limited benefit.Hybrid capture-based comprehensive genomic profiling (CGP) was performed for 412 intrahepatic cholangiocarcinomas (IHCCAs), 57 extrahepatic (EHCCAs), 85 gallbladder carcinomas (GBCAs). The mutational profile correlated with the clinical outcome standard experimental therapies 321 patients. Clinical variables, detected mutations, administered were overall survival (OS) in...
<h3>Importance</h3> Isocitrate dehydrogenase 1 (<i>IDH1</i>) variations occur in up to approximately 20% of patients with intrahepatic cholangiocarcinoma. In the ClarIDHy trial, progression-free survival as determined by central review was significantly improved ivosidenib vs placebo. <h3>Objective</h3> To report final overall (OS) results from which aimed demonstrate efficacy (AG-120)—a first-in-class, oral, small-molecule inhibitor mutant IDH1—vs placebo for unresectable or metastatic...
Standard therapies for localized inoperable intrahepatic cholangiocarcinoma (IHCC) are ineffective. Advances in radiotherapy (RT) techniques and image guidance have enabled ablative doses to be delivered large liver tumors. This study evaluated the effects of RT dose escalation treatment IHCC.Seventy-nine consecutive patients with IHCC were identified treated definitive from 2002 2014. At diagnosis, median tumor size was 7.9 cm (range, 2.2 17 cm). Seventy (89%) received systemic chemotherapy...
Biliary cancers are highly aggressive tumors that often diagnosed an advanced disease stage and have a poor outcome with systemic therapy. Recent efforts towards molecular characterization identified subset of biliary patients HER2/neu amplification or mutation. is associated response to HER2/neu-directed therapy in breast gastric cancers. However, the efficacy HER2/neu-targeted unknown.We retrospectively reviewed cases gallbladder cancer cholangiocarcinoma genetic aberrations protein...
WHAT'S NEW SINCE THE 2010 GUIDELINES? Inclusion of guidance for the diagnosis and management cholangiocarcinoma (CCA) in patients with without primary sclerosing cholangitis (PSC) (Figures 5, 8, 9). Introduction term relevant stricture, defined as any biliary stricture common hepatic duct or ducts associated signs symptoms obstructive cholestasis and/or bacterial (Table 1). In equivocal MRI cholangiopancreatography (MRI/MRCP) findings, a repeated high‐quality MRI/MRCP should be performed...
Pancreatic cancer has a poor prognosis and limited treatment options. Approximately 9% of pancreatic cancers harbor germline or somatic BRCA1 BRCA2 (BRCA1/2) mutation. Because poly (ADP-ribose) polymerase inhibitors have significant activity in BRCA1/2-mutant ovarian breast cancers, RUCAPANC investigated the efficacy safety rucaparib cancer.RUCAPANC enrolled patients with measurable locally advanced/metastatic who had received one to two prior chemotherapy regimens. Patients oral (600 mg...
LBA490 Background: Biliary tract cancers (BTCs) are a heterogeneous group of malignancies with dismal prognosis. Gemcitabine-based regimens the standard care in advanced disease, but median overall survival (OS) is roughly 12 months. The addition albumin-bound paclitaxel to gemcitabine and cisplatin (GAP) demonstrated promising efficacy 60 patient, single-arm phase II study (Shroff et al, JAMA Oncol 2019), observed OS 19.2 Methods: SWOG 1815 randomized, open-label, III trial comparing GAP...
Targeted therapies have transformed clinical management of advanced biliary tract cancer (BTC). Cell-free DNA (cfDNA) analysis is an attractive approach for genomic profiling that overcomes many limitations traditional tissue-based analysis. We examined cfDNA as a tool to inform patients with BTC and generate novel insights into tumor biology.We analyzed next-generation sequencing data 2068 samples from 1671 generated Guardant360. carried out annotation on multi-institutional subset (n =...
The phosphoinositide 3-kinase (PI3K)/Akt pathway is constitutively activated in pancreatic cancer and the mammalian target of rapamycin (mTOR) kinase an important mediator for its signaling. Our recent vitro studies suggest that prolonged exposure cells to mTOR inhibitors can promote insulin receptor substrate-PI3K interactions paradoxically increase Akt phosphorylation cyclin D1 expression (negative feedback loop). addition erlotinib down-regulate rapamycin-stimulated results synergistic...
FGFR genetic aberrations (GAs) occur in an estimated 10% to 16% of intrahepatic cholangiocarcinomas (CCAs). The natural history CCA with GAs, the prognostic role coexisting and outcome FGFR-targeted inhibitors are unknown.Patients GAs were identified using next-generation sequencing or fluorescence situ hybridization from four tertiary cancer centers compared wild-type counterparts. Data reviewed included demographic, treatment, overall survival (OS), GA data. Fisher's exact test,...
We previously demonstrated that a major pathologic response to preoperative therapy, defined histopathologically by the presence of less than 5% viable cancer cells in surgical specimen, is an important prognostic factor for patients with pancreatic ductal adenocarcinoma. However, our knowledge, most likely experience significant therapy are undefined.To identify clinical factors associated large cohort who underwent and pancreatectomy adenocarcinoma.Retrospective review prospectively...
Abstract Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a heterogeneous disease with variable presentations and natural histories of disease. We hypothesized that different morphologic characteristics PDAC tumors on diagnostic computed tomography (CT) scans would reflect their underlying biology. Experimental Design: developed quantitative method to categorize the morphology pretherapy CT from multiple datasets patients resectable metastatic correlated these patterns clinical/pathologic...